-- エルデネ・リソース・デベロップメント(ERD.TO)は月曜日、モンゴルのバヤン・クンディ金鉱山が第1四半期に目標生産量の94%を達成したと発表した。 同鉱山は第1四半期に商業生産を開始し、1日平均1,675トン、合計15万1,000トンの鉱石を処理した。 バヤン・クンディ鉱山は、平均処理量が定格生産能力の約90%に達し、金回収率は平均96%を超え、最新のフィージビリティスタディの予測を上回った。 エルデネによると、同鉱山はこれまでに1万5,961オンスの金を生産している。 エルデネ・リソースとモンゴリアン・マイニングの合弁会社であるエルデネ・モンゴルは、金8,527オンスと銀3,135オンスを販売し、第1四半期の売上高は4,200万米ドルとなった。金の平均価格は1オンスあたり4,872ドル、銀の平均価格は1オンスあたり80ドルだった。
Related Articles
Exelon Seen Offsetting PECO Rate Case Withdrawal Impact Over Time, RBC Says
Exelon (EXC) will eventually be able to offset the negative impact on revenue of the withdrawal of rate cases by its Pennsylvania-based energy utility subsidiary PECO, RBC Capital Markets said.The subsidiary withdrew its electric and gas rate cases with the Pennsylvania Public Utility Commission, which were requests for a $429 million electric revenue increase and an $81 million gas increase, the brokerage said in a Friday note.They estimate that PECO will miss about $130 million to $200 million in incremental revenue, translating to a negative impact of about $0.09 to $0.14 on earnings per share in 2027.Exelon will be able to mitigate the drag through new rate hike requests, managing operations and maintenance costs, and an accelerated capital plan company-wide.The investment firm noted that Exelon maintained its 2026 adjusted EPS guidance of $2.81 to $2.91 and expressed confidence in its ability to achieve the high end of its annual EPS growth target of 5% to 7% through 2029.BC maintained its sector-perform rating on the stock and lowered its price target to $48 from $51.Price: $47.18, Change: $+0.15, Percent Change: +0.33%
Pfizer's Upcoming Tafamidis Bench Trial Shows Asymmetric Upside, RBC Capital Markets Says
Pfizer's (PFE) tafamidis bench trial commencing next week shows an asymmetric upside based on modeling of three core outcome scenarios, creating a $5 billion net present value differential between bear and bull cases, RBC Capital Markets said in a Monday note.The investment firm said the lawsuit hinges on the '441 polymorph patent that is set to expire in 2035 and is "scientifically the weakest," as the '695 compound and '696 method-of-use patents are expected to hold.RBC estimated a 19% probability for a Pfizer win, with the company showing infringement and getting protection through 2035, representing over $6 billion in net present value.There is a 60% probability for a tie, with generics entry from around 2032, representing net present value of over $3 billion, according to the note.Additionally, there's a 21% probability for Pfizer losing the case and its polymorph patent is held as not infringed, translating into 2028 entry of generics, which is currently priced in the company's stock, the firm said.RBC maintained its underperform rating on the stock with a $25 price target.Price: $27.77, Change: $+0.21, Percent Change: +0.74%
US Equity Indexes Retreat From Records as Iran Peace Talks Hang in Balance
US equity indexes slipped, while crude oil futures rose amid high-stakes Middle East diplomacy to bring Iran back to the negotiating table in Pakistan for a second round of peace talks.The Nasdaq Composite fell 0.6% to 24,308.2, with the S&P 500 down 0.4% to 7,100.3, after breaking records last week when President Donald Trump talked up the likelihood of reaching an Iran peace deal before the end of the current, two-week ceasefire on Tuesday. The Dow Jones Industrial Average fell 0.3% to 49,284.5.Consumer discretionary, communication services, and technology led decliners intraday. Energy and materials were among the biggest gainers.West Texas Intermediate crude oil futures jumped 5.1% to $88.16, and Brent crude futures advanced 5% to $94.91.Vice President JD Vance and top US officials are expected to depart Tuesday for Islamabad, Pakistan, ahead of a potential second round of talks with Iran, CNN reported Monday, citing sources. Iran is considering attending peace talks, a senior official from the Middle East nation told Reuters on Monday, following moves by Islamabad to end a US blockade of Tehran's ports, a major hurdle for the country under threat of widespread attack to rejoin peace efforts.Trump said it's "highly unlikely" he would extend the two-week ceasefire with Iran if a deal is not reached before it ends, and said the Strait of Hormuz would remain blocked until an agreement is finalized, Bloomberg reported. The US president said in a Monday phone interview that the second round of talks with Iran is set to begin Tuesday.